Combined oral contraceptives in the therapy of acne
- 作者: Grodnitskaya E.E.1
-
隶属关系:
- Center for Family Planning and Reproduction, Moscow Healthcare Department
- 期: 编号 3 (2015)
- 页面: 100-102
- 栏目: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/247433
- ID: 247433
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
Acne is an androgen-dependent lesion in the pilosebaceous unit; in this connection, it is reasonable to use combined oral contraceptives containing antiandrogenic progestins for the treatment of this disease in conjunction with other therapy options. The paper provides a physiological rationale for the use of dienogest-containing agents to treat acne.
全文:
作者简介
Elena Grodnitskaya
Center for Family Planning and Reproduction, Moscow Healthcare Department
Email: elenal778@mail.ru
MD, PhD, obstetrician-gynecologist
参考
- Salvaggio H.L., Zaenglein A.L. Examining the use of oral contraceptives in the management of acne. Int. J. Womens Health. 2010; 2: 69-76.
- Perkins A.C., Maglione J., Hillebrand G.G., Miyamoto K., Kimball A.B. Acne vulgaris in women: prevalence across the life span. J. Womens Health (Larchmt). 2012; 21(2): 223-30.
- Mallon E., Newton J.N., Klassen A., Stewart-Brown S.L., Ryan T.J., Finlay A.Y. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br. J. Dermatol. 1999; 140(4): 672-6.
- Cunliffe W.J. Acne and unemployment. Br. J. Dermatol. 1986; 115(3): 386.
- Nast A., Dréno B., Bettoli V., Degitz K., Erdmann R., Finlay A.Y. et al.; European Dermatology Forum. European evidence-based (S3) guidelines for the treatment of acne. J. Eur. Acad. Dermatol. Venereol. 2012; 26 (Suppl. 1): 1-29.
- Chen W., Yang C.C., Sheu H.M., Seltmann H., Zouboulis C.C. Expression of peroxisome proliferator-activated receptor and CCAAT/enhancer binding protein transcription factors in cultured human sebocytes. J. Invest. Dermatol. 2003; 121(3): 441-7.
- Rosenfield R.L., Deplewski D., Kentsis A., Ciletti N. Mechanisms of androgen induction of sebocyte differentiation. Dermatology. 1998; 196(1): 43-6.
- Thiboutot D., Chen W. Update and future of hormonal therapy in acne. Dermatology. 2003; 206(1): 57-67.
- Kraft J., Freiman A. Management of acne. Can. Med. Assoc. J. 2011; 183(7): E430-5.
- Whitney K.M., Ditre C.M. Management strategies for acne vulgaris. Clin. Cosmet. Investig. Dermatol. 2011; 4: 41-53.
- Arowojolu A.O., Gallo M.F., Lopez L.M., Grimes D.A. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst. Rev. 2012; (6): CD004425.
- Oettel M., Bervoas-Martin S., Elger W., Golbs S., Hobe G., Kaufmann G. et al. A 19-norprogestin without 17a-ethinyl group II: Dienogest from a pharmacokinetic point of view. Drugs Today. 1995; 31(7): 499-516.
- Palombo-Kinne E., Schellschmidt I., Schumacher U., Gräser T. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate. Contraception. 2009; 79(4): 282-9.
- Eichenfield L.F., Krakowski A.C., Piggott C., Del Rosso J., Baldwin H., Friedlander S.F. et al.; American Acne and Rosacea Society. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics. 2013; 131(Suppl. 3): S163-86.
补充文件
